CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person.
- TD Cowen 45th Annual Health Care Conference: Corporate Presentation and Q&A on Tuesday, March 4, 2025, at 10:30 a.m. ET in Boston, Massachusetts
- Leerink Global Healthcare Conference: Fireside chat on Monday, March 10, 2025, at 2:20 p.m. ET in Miami, Florida
A live webcast of both presentations can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.
About Amylyx Pharmaceuticals
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative, neuroendocrine, and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.
                                        
                                        
                                        Media 
                                        
                                        Amylyx Media Team
                                        
                                        +1 (857) 799-7274
                                        
                                        amylyxmediateam@amylyx.com
                                        
                                    
                                        
                                        Investors 
                                        
                                        Lindsey Allen
                                        
                                        Amylyx Pharmaceuticals, Inc.
                                        
                                        +1 (857) 320-6244
                                        
                                        Investors@amylyx.com